Author + information
- Zhang Jianghua and
- Baopeng Tang
MicroRNA 21 (miRNA-21) promotes the development of cardiac fibrosis, hypertrophy and heart failure. However, whether it can be used as a biomarker for diagnosis and prognosis of heart failure is unknown. Our study assessed circulating miRNA-21 as a viable indicator for diagnosis and prognosis of heart failure.
The levels of miRNA-21 and brain natriuretic peptide were measured in serum obtained from the peripheral vein (miRNA-21-PV) and coronary sinus (miRNA-21-CS) of 80 heart failure patients and 40 control individuals via reverse transcription and quantitative polymerase chain reaction and ELISA, respectively. Correlations between circulating miRNA-21 and diagnosis, severity, prognosis and re-hospitalization rate of heart failure were evaluated using statistical analysis.
Serum miRNA-21-PV and miRNA-21-CS levels of heart failure patients were significantly higher than those of control subjects, and were also correlated well with ejection fraction and brain natriuretic peptide. Both were determined to have high sensitivity and specificity for diagnosing heart failure. Follow-up of the heart failure patients indicated that miRNA-21-PV and miRNA-21-CS correlated with prognosis, and miRNA-21-CS was efficient in predicting re-hospitalization for heart failure.
Circulating miRNA-21 has potential to be a biomarker of heart failure.